Press Releases

  • February 12, 2015 – link:  Sale Molecular Response’s PDX business unit to Crown Bioscience, Inc.
  • September 15, 2015 – link:  Former head of Translational Medicine Oncology at Medimmune, Brett Hall Ph.D., appointed as new CEO.  Change in core business strategy to focus on: (1.) Biospecimen Storage, (2.) Tumor Microenvironment Research and (3.) Drug Discovery.
  • March 22, 2016 – link:  Molecular Response Expands Its Biospecimen Storage Capacity to Provide Biorepository Services